Skip to content
value.today
Biotage AB logo

Biotage AB

BIOT.ST
$1.0 Blast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$195 M
For year ending December-2024
Net income
$27 M
13.8% margin
Official annual report (ESEF)
Employees
—

Biotage AB in brief

Biotage AB is a listed company in the Medical Instruments industry, based in Sweden. Its last known market value was $1.0 B (January 2024); there is no current figure. In the year to December 2024 it had sales of $195 M and a net profit of $27 M, about 14 cents of profit for every dollar of sales. Its shares trade under the symbol BIOT.ST (Stockholm).

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

About Biotage AB

Biotage offer workflow solutions and products to customers in drug discovery and development, analytical testing and water and environmental testing. They serve their customers in the market segments of pharmaceutical, biotech, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability. The company annual revenue is 1,232 million SEK and annual net income is 205 million SEK as on 2021. The headquarters is in Sweden.

Biotage AB timeline

2 events, 1997–2016
  1. 1997
  2. 🏁
    · approximate
    Incorporated as Biotage AB
  3. 2016
  4. •
    Legal Entity Identifier issued
    LEI 529900SR87NBUKX74L58 registered.

Events of Biotage AB from the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$436 M$873 M$1.3 B$1.7 B20202021202220232024

World rank over time

▼ down 408 places since 2020
2020-01-01: #8009#8,00920202021-01-01: #7574#7,57420212022-01-07: #7128#7,12820222022-12-25: #7706#7,70620222023-07-30: #8734#8,73420232024-01-05: #8417#8,4172024

Rank in Sweden: #116 (Jan 2020) · #127 (Jan 2021) · #125 (Jan 2022) · #101 (Dec 2022) · #116 (Jul 2023) · #121 (Jan 2024)

Key ratios

market cap and latest results
P/E ratio
—
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
13.8%
Operating margin
18.6%
Return on equity
7.2%
Liabilities / assets
19.4%
Revenue growth
+11.0%
R&D / revenue
8.8%

Financial history

USD · fiscal years · source: official annual reports (ESEF)
RevenueNet income
Fiscal year ending Dec 2023: revenue $175M, net income $23M$175MFY23Fiscal year ending Dec 2024: revenue $195M, net income $27M$195MFY24
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2024$195M+11.0%$36M$27M13.8%
Dec 2023$175M—$30M$23M13.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2024$39M$8M$31M$0.34—
Dec 2023$27M$2M$24M$0.31—

Annual results

Revenue
$195 M
Operating income
$36 M
Net income
$27 M

For year ending December-2024 · source: official annual report (ESEF)

Balance sheet

Total assets
$463 M
Total liabilities
$90 M
Total equity
$373 M

As of December-2024

Ownership and subsidiaries

Biotage AB directly owns 1 registered entity:

Biotage AB scorecard#

Passes 4 of the 5 checks that could be worked out. Fiscal year 2024.

  • Valuationnot known
  • Growth2 of 2
  • Profitability2 of 3
  • Financial healthnot known
  • Shareholder returnsnot known

Worked out from the statements as filed (esef), the medians of Medical Instruments, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2024#

Worked out from Biotage AB's statements, beside the median of Medical Instruments.

Biotage AB: main financial ratios in 2024
Ratio2024Median of peers
Operating margin18.6%7.0%
Net margin13.8%3.3%
Return on equity7.3%2.4%
Revenue growth11.0%8.3%
Free cash flow margin15.8%5.5%

6of 6on the Piotroski tests of financial strength

Biotage AB: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in SEK millions; per-share figures in SEK; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Biotage AB: statements by fiscal year
PeriodTrendFY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue2,0561,8621,5661,2321,092
Cost of revenue767713618477426
Gross profit1,2891,149948755667
Research and development1801591099172
General and administrative264212150117105
Operating income383314327271206
Interest and finance income1230351026
Interest expense and finance costs674114129.0
Income before tax328303348269223
Income tax4457806447
Net income including minority interests284246268205175
Net income attributable to shareholders284246268205175
Earnings per share, basic3.553.344.063.132.69
Earnings per share, diluted3.553.334.043.132.69
Shares, weighted average (basic)8074666565
Shares, weighted average (diluted)8074666565
Dividends per share1.65—1.60——
Balance sheet
Cash and cash equivalents434594441311371
Receivables357321223180194
Inventory458437305237160
Current assets1,3231,4471,031774752
Property, plant and equipment245187967653
Right-of-use (leased) assets8597665251
Goodwill2,5632,391794741290
Other intangible assets——172185129
Non-current assets3,7463,4841,3081,218683
Total assets5,1044,9312,3391,9921,434
Accounts payable——575651
Current liabilities573705417313217
Long-term debt150150150150110
Lease liabilities (non-current)6676423031
Non-current liabilities409569285307227
Total liabilities————1,434
Retained earnings1,5371,3781,2291,063956
Total equity4,1133,6571,6371,371990
Total liabilities and equity5,1044,9312,3391,992—
Shares outstanding——666665
Cash-flow statement
Cash from operating activities413284341353279
Capital expenditure−89−26−35−23−18
Intangible assets bought−80−65−35−33−43
Acquisitions, net of cash acquired−287−125−12−2820
Cash from investing activities−45635−84−341−62
Debt issued——1501500
Debt repaid−30−38−180−134—
Shares issued2.00———
Shares bought back——000
Dividends paid−128−106−102−980
Cash from financing activities−156−142−133−82−23
Exchange-rate effect on cash39−247.09.0−10
ReportESEFESEFESEFESEFESEF

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Dec 31, 2024

Where Biotage AB operates: 1 country#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.

Present: offices, subsidiaries, branches or revenue (1 country)Nothing on fileDots mark countries too small to see. Hover, tap or tab to a country for its figures.

Only the headquarters country is on file for Biotage AB: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.

Biotage AB: countries of operation
CountryPresenceRevenue there
🇸🇪 SwedenHeadquarters2 offices1 subsidiary—

How Biotage AB compares in Medical Instruments

  • Revenue$195 M · higher than 32% of 121
  • Net margin13.8% · higher than 69% of 115
  • Revenue growth11.0% · higher than 59% of 50

Peer comparison · Medical Instruments

CompanyMarket capP/ENet marginRev. growth
Biotage AB🇸🇪$1.0 B—13.8%+11.0%
Intuitive Surgical, Inc.🇺🇸$155.6 B52.6×25.5%+20.5%
EssilorLuxottica S.A.🇫🇷$88.0 B32.1×8.1%+4.5%
HOYA Corporation🇯🇵$56.2 B32.8×25.4%—
Becton, Dickinson and Company🇺🇸$54.0 B57.4×4.2%+8.2%
Alcon Inc.🇨🇭$37.1 B37.9×9.4%+4.9%
ResMed Inc.🇺🇸$35.3 B22.1×27.8%+9.8%
West Pharmaceutical Services, Inc.🇺🇸$27.1 B42.4×18.8%+6.3%
Terumo Corporation🇯🇵$24.9 B27.0×12.0%—

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2024
Balance sheet:
As of December-2024
Profile updated:
Nov 15, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Biotage AB? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Biotage AB's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Biotage AB? Suggest a correction